BofA cuts Mankind Pharma stock target to INR2,150

Published 22/05/2025, 05:16
BofA cuts Mankind Pharma stock target to INR2,150

On Thursday, BofA Securities analysts adjusted their outlook on Mankind Pharma Ltd (MANKIND:IN), lowering the price target to INR2,150 from INR2,250, while maintaining an Underperform rating on the stock. The revision comes after the company reported financial results that fell short of expectations.

Mankind Pharma announced revenue of Rs30.8 billion and an EBITDA margin of 22.2%, which was below both BofA Securities’ and consensus estimates. Analysts at BofA Securities had projected a margin of 23%, while the broader market expectation stood at 25.6%. Despite a pickup in 4Q organic India growth to 10% from 7% in the previous quarter, concerns have been raised about the moderation in BSV sales and the impact of one-off costs on profit margins.

The company provided guidance for its core and BSV portfolio, suggesting a significant improvement by FY26. However, the anticipated margin guidance of 25-26% could potentially lead to a consensus earnings downgrade. In response to the company’s latest financial figures and future projections, BofA Securities has revised its EBITDA estimates down by 3-4%.

The analysts reasserted their Underperform rating, indicating skepticism about the company’s short-term performance prospects. The revised price target of INR2,150 reflects the updated earnings estimates and the challenges faced by Mankind Pharma in achieving its margin guidance amidst the integration process and additional costs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.